NFE2L2 and susceptibility to pneumonia measurement: Since SARS-CoV-2 mediates Nrf2 suppression and limits host anti-inflammatory response (Cuadrado et al., 2020; McCord et al., 2020; Olagnier et al., 2020; Emanuele et al., 2021; Fratta Pasini et al., 2021), targeting Nrf2 is therefore essential for the treatment of diseases characterized by enhanced oxidative stress and inflammation, such as aging and COVID-19-induced pneumonia and ARDS (Lewis et al., 2010; Lee, 2018; Robledinos-Antón et al., 2019; Schmidlin et al., 2019; Lin and Yao, 2020).